Navigation Links
Solos Endoscopy Reduces Liabilities by More than $570,000
Date:4/25/2012

BOSTON, April 25, 2012 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) is pleased to announce that the Company has successfully reduced its liabilities on its Balance Sheet by more than $570,000.  As a result, the Company expects to achieve a Positive Net Book Value when it posts its second quarter financials, and show significant reduction of its liabilities for the period ended March 31, 2012.

Solos Endoscopy recently issued Preferred Stock valued at $10 per share in order to reduce its liabilities by $315,000 and has reduced the remaining $140,000 in Preferred Stock payable as a forgiveness of debt. In addition, as result of other equity investments received, Solos Endoscopy has been able to reduce its payables by an additional $120,000.  Solos Endoscopy previously consummated agreements, which resulted in the forgiveness of $457,471 in debt for the Company. The signed settlement agreement and new consulting agreement resulted in a reduction of ongoing expenses by approximately $60,000 per quarter that carried over into 2012. As a result, Solos Endoscopy was able to reduce its total liabilities to approximately $285,000.

Throughout 2011 and the first quarter of 2012, Solos has been focused on reducing its debt, and strengthening its Balance Sheet.  The Company expects to be virtually debt free by the 2nd Quarter of 2012, and will begin to build its asset base by purchasing additional inventory of endoscopic equipment.   Solos Endoscopy has developed several new modifications to its endoscopic instrument lines to accommodate the continual advances in Laparoscopic surgical procedures. The significant advances over the past several years have led to a number of advantages to the patient with laparoscopic surgery versus an open procedure (laparotomy). The demand for endoscope services is increasing due to an increase in the aging and chronically ill population worldwide. Advancements in endoscopic technologies and inclusion of various types of lighting sources, video cameras, real-time conversion of data into three-dimensional images are also driving this market.

The Solos MammoView® system is currently in use at various teaching hospitals across the United States. From July through November, mammary ductoscopy instrument sales accounted for approximately 40% of the total sales for the period.

"Solos management has made a real effort to reduce debt and position the Company for profitability.  By working with its various creditors, management believes the Company can be virtually debt free by the 2nd quarter of 2012," stated Bob Segersten, President of Solos Endoscopy, Inc.

About Solos Endoscopy, Inc.:

Solos Endoscopy, Inc. is a HealthCare instrument company whose mission is to develop and market high quality and innovative instruments for the screening, diagnosis, treatment and management of medical conditions. Additional information on its FDA approved products is available on the Company's website at: www.solosendoscopy.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:
Amanda Segersten
rsegersten@solosendoscopy.com   


'/>"/>
SOURCE Solos Endoscopy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solos Endoscopy to Launch New SteriTAP™ Endoscopic Instrument Line
2. Solos Endoscopy, Inc. Successfully Completes Level I FDA Inspection
3. Solos Endoscopy, Inc. Announces Retirement of 150 Million Common Shares
4. Solos Endoscopy, Inc. is Primed for Growth in 2012
5. Solos Endoscopy, Inc. Reports Significant Sales From Its MammoView® Instrument Line
6. Solos Endoscopy Finishes the 3rd Quarter With a Net Profit
7. Solos Endoscopy Poised for Tremendous Growth in Multi-Billion Dollar Endoscopic Market
8. Solos Endoscopy Goes Google
9. Solos Endoscopy Finishes the 3rd Quarter Strong
10. Solos Endoscopy to Support National Breast Cancer Foundation With Sales of Its MammoView® Breast Endoscopy Components to US Hospitals
11. Solos Endoscopy to Market its MammoView® Breast Endoscopy Components to US Hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Arvinas LLC, a private biotechnology company creating ... today announced the presentation of new preclinical data on ... session at the American Society of Clinical Oncology 2017 ... FL. "The new data ... potential of PROTACs to drive durable and robust responses ...
(Date:2/17/2017)... Research and Markets has announced the addition of ... their offering. ... separate comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ... Also, a six-year historic analysis is provided for these markets. Market data ...
(Date:2/17/2017)... 17, 2017  Featuring new and ... the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  Royal ... global leader in health technology,  will ... population health management, acute healthcare informatics ... a highly secure, cloud-based ecosystem. Visitors ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers ... of controlled and non-controlled substances plus the ability to manage orders on their ... States now accept electronic prescriptions, according to the Office of the National Coordinator ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Carol Francis' goals for each and every seminar, session and class she ... demonstrate five different brainwave tools which help energize creativity, focus mental functions, enhance ...
(Date:2/17/2017)... ... 17, 2017 , ... Access today announced that it will ... February 19-23. Visitors to the company’s booth (#1778) will be the first to ... solution in healthcare . , Since it first introduced Electronic Signature more ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended CHI's 8th ... of clinical trial planning and management. Pharmica discussed the importance of effective project ... attendees stopping by Pharmica’s booth were able to demo its cloud-based Resource ...
(Date:2/17/2017)... GA (PRWEB) , ... February 17, 2017 , ... Like ... to reduce readmissions. Driven in large part by the Hospital Readmission Reduction Program (HRRP), ... been a key focus area for hospitals across the nation. While many providers are ...
Breaking Medicine News(10 mins):